A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region (ASC4Young)
ASC4Young: Real-World Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region
The aim of this study is to evaluate the real-world effectiveness and safety of asciminib among young adults with chronic myeloid leukemia (CML) across the Gulf region. The data source for this study will consist of routinely collected clinical information documented within the electronic health records (EHR) of participating centers.
調査の概要
状態
条件
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Novartis Pharmaceuticals
- 電話番号:+41613241111
- メール:novartis.email@novartis.com
研究連絡先のバックアップ
- 名前:Novartis Pharmaceuticals
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
CML patients who initiate asciminib between 01 May 2023 and 31 May 2026 in participating centers across the Gulf region.
説明
Inclusion Criteria
- Confirmed diagnosis of Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP)
- Adult patients aged ≥ 18 years at the index date (or adult as defined by applicable national regulations)
- Documented exposure to asciminib during the identification period (May 2023 to May 2026)
- Provision of signed informed consent for secondary use of data, or an ethics committee-approved waiver of consent, where applicable (including for deceased patients or where data were previously collected within the EHR system)
Exclusion Criteria
- Patients who do not meet the eligibility criteria specified above
- Patients with insufficient medical record documentation to determine asciminib exposure or key study outcomes
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:RETROSPECTIVE
コホートと介入
グループ/コホート |
|---|
|
Young Adults Cohort
CML patients aged ≤ 40 years at the first documented asciminib administration. |
|
Older Adults Cohort
CML patients aged > 40 years at the first documented asciminib administration. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Major Molecular Response (MMR) Rate in Young Adults
時間枠:Approximately 12 Months
|
MMR is defined as a BCR::ABL1 level on the International Scale (BCR::ABL1 IS) ≤ 0.1%. |
Approximately 12 Months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of Adverse Events (AEs)
時間枠:Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Number of Treatment Interruptions Due to AEs
時間枠:Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Duration of Treatment Interruptions Due to AEs
時間枠:Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Time to Treatment Discontinuation due to Adverse Events (TTDAE)
時間枠:Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Proportion of Patients who Achieve an Early Molecular Response Milestone of BCR::ABL1 IS ≤ 10% After 3 Months of Treatment
時間枠:3 months
|
3 months
|
|
|
Proportion of Patients who Achieve an Early Molecular Response Milestone of BCR::ABL1 IS ≤ 1% After 6 Months of Treatment
時間枠:6 months
|
6 months
|
|
|
Number of Patients With Prior Tyrosine Kinase Inhibitor (TKI) Treatment
時間枠:Up to 12 months prior to Baseline
|
Up to 12 months prior to Baseline
|
|
|
Duration of CML at Time of Asciminib Treatment Initiation
時間枠:Baseline
|
Baseline
|
|
|
Asciminib Starting Dose
時間枠:Baseline
|
Baseline
|
|
|
Number of Treatment Interruptions
時間枠:Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Duration of Treatment Interruptions
時間枠:Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Number of Patients by Reasons for Treatment Interruptions and Subsequent Treatment Switching
時間枠:Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Number of Patients by Reason for Treatment Switch
時間枠:Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Number of Patients by Type and Severity of AEs
時間枠:Approximately 3, 6, and 12 months
|
Number of patients by type and severity of AEs including serious AEs and grade ≥ 3 AEs according to the Common Terminology Criteria for Adverse Events (CTCAE) v6.0. |
Approximately 3, 6, and 12 months
|
|
Incidence of AEs Leading to Dose Modifications
時間枠:Approximately 3, 6, and 12 months
|
Dose modifications include treatment interruptions and dose reductions. |
Approximately 3, 6, and 12 months
|
|
MMR in Patients Aged > 40 years
時間枠:Approximately 12 months
|
MMR is defined as BCR::ABL1 IS ≤ 0.1%. |
Approximately 12 months
|
|
Rate of Deep Molecular Response
時間枠:Approximately 12 months
|
Deep molecular response includes:
|
Approximately 12 months
|
|
Number of Patients With Dose Modifications
時間枠:Approximately 3, 6, and 12 months
|
Number of patients with dose modifications including up titration or dose reduction. |
Approximately 3, 6, and 12 months
|
|
Number of Patients by Clinicopathological Characteristics
時間枠:Up to 12 months pre-Baseline, Baseline, and approximately 3, 6 , and 12 months post-Baseline
|
Clinicopathological characteristics include:
|
Up to 12 months pre-Baseline, Baseline, and approximately 3, 6 , and 12 months post-Baseline
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Novartis Pharmaceuticals、Novartis Pharmaceuticals
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。